Latest Chimeric antigen receptor Stories
Exclusive Licensing Agreement for CAR T Cell, TCR, NK Cell Programs and Associated Technologies for the Development of Non-Viral Adoptive Cellular Therapies GERMANTOWN, Md., BOSTON,
Alliance Combines Amgen's Oncology Targets and Kite's Leading CAR T Cell Therapy Platform to Develop new Therapeutic Candidates THOUSAND OAKS, Calif.
Developing Next Generation Cancer Immunotherapy with "Off-the-Shelf" Chimeric Antigen Receptor-Tumor Attacking Natural Killer (CAR-TNK(TM)) Cell Lines SAN DIEGO and CARDIFF-BY-THE-SEA,
--CHOP-Led Pilot Study Engineers Patients' Own Immune Cells to Hunt Down Cancer Cells in Blood-- PHILADELPHIA, Dec.
- Data shows 36 of 39 pediatric patients with relapsed/refractory acute lymphoblastic leukemia (r/r ALL) (92%) experienced complete remissions EAST HANOVER, N.J., Dec.
SEATTLE, Nov. 18, 2014 /PRNewswire-USNewswire/ -- Juno Therapeutics, Inc.
GREENWICH, Conn., Aug.
Total Investment Tops $300M in Less Than 12 Months SEATTLE, Aug.
SANTA MONICA, Calif., June 6, 2014 /PRNewswire/ -- Kite Pharma, Inc., a clinical-stage biotechnology company focused on developing engineered autologous T cell therapy (eACT(TM)) products for
- The word or words serving to define another word or expression, as in a dictionary entry.